Back, David, Belperio, Pamela, Bondin, Mark, Negro, Francesco, Talal, Andrew H, Park, Caroline, Zhang, ZhenZhen, Pinsky, Brett, Crown, Eric, Mensa, Federico J et al (show 1 more authors)
(2019)
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis.
JOURNAL OF VIRAL HEPATITIS, 26 (8).
pp. 951-960.
Text
Back_et_al-2019-Journal_of_Viral_Hepatitis.pdf - Published version Download (606kB) | Preview |
Abstract
Although direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection are highly efficacious and safe, treatment initiation is often limited in patients with neuropsychiatric disorders due to concerns over reduced treatment adherence and drug-drug interactions. Here, we report adherence, efficacy, safety and patient-reported outcomes (PROs) from an integrated analysis of registrational studies using the pangenotypic DAA regimen of glecaprevir and pibrentasvir (G/P). Patients with chronic HCV genotypes 1-6 infection with compensated liver disease (with or without cirrhosis) receiving G/P for 8, 12 or 16 weeks were included in this analysis. Patients were classified as having a psychiatric disorder based on medical history and/or co-medications. Primary analyses assessed treatment adherence, efficacy (sustained virologic response at post-treatment week 12; SVR12), safety and PROs. Among 2522 patients receiving G/P, 789 (31%) had a psychiatric disorder with the most common diagnoses being depression (64%; 506/789) and anxiety disorders (27%; 216/789). Treatment adherence was comparably high (>95%) in patients with and without psychiatric disorders. SVR12 rates were 97.3% (768/789; 95% CI = 96.2-98.5) and 97.5% (1689/1733; 95% CI = 96.7-98.2) in patients with and without psychiatric disorders, respectively. Among patients with psychiatric disorders, SVR12 rates remained >96% by individual psychiatric diagnoses and co-medication classes. Overall, most adverse events (AEs) were mild-to-moderate in severity with serious AEs and AEs leading to G/P discontinuation occurring at similarly low rates in both patient populations. In conclusion, G/P treatment was highly efficacious, well-tolerated and demonstrated high adherence rates in patients with chronic HCV infection and psychiatric disorders.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | chronic hepatitis C, drug interactions, mental disorders, sustained virologic response, treatment adherence and compliance |
Depositing User: | Symplectic Admin |
Date Deposited: | 08 Aug 2019 10:09 |
Last Modified: | 19 Jan 2023 00:35 |
DOI: | 10.1111/jvh.13110 |
Open Access URL: | https://doi.org/10.1111/jvh.13110 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3051268 |